Traws Pharma (NASDAQ:TRAW) Releases Quarterly Earnings Results, Beats Estimates By $0.18 EPS

Traws Pharma (NASDAQ:TRAW) released its quarterly earnings results on Friday. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.18, FiscalAI reports.

Traws Pharma Trading Down 4.8%

NASDAQ TRAW opened at $0.57 on Friday. The firm’s 50 day simple moving average is $0.73 and its 200 day simple moving average is $1.37. The firm has a market capitalization of $8.65 million, a price-to-earnings ratio of -0.33 and a beta of 1.57. Traws Pharma has a 1 year low of $0.43 and a 1 year high of $3.27.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TRAW shares. Citigroup lowered shares of Traws Pharma to a “neutral” rating in a research report on Monday, June 15th. Weiss Ratings cut Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. LADENBURG THALM/SH SH downgraded Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Finally, HC Wainwright restated a “negative” rating and issued a $1.00 price target on shares of Traws Pharma in a research report on Thursday, June 18th. Three research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Traws Pharma presently has an average rating of “Reduce” and a consensus target price of $1.00.

Institutional Investors Weigh In On Traws Pharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TRAW. Ikarian Capital LLC boosted its holdings in shares of Traws Pharma by 2,280.0% in the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock valued at $766,000 after purchasing an additional 649,649 shares in the last quarter. Squadron Capital Management LLC acquired a new position in shares of Traws Pharma during the 4th quarter worth $806,000. Adage Capital Partners GP L.L.C. lifted its position in shares of Traws Pharma by 121.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after buying an additional 400,000 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after buying an additional 31,502 shares during the last quarter. Finally, Boothbay Fund Management LLC acquired a new stake in Traws Pharma in the fourth quarter valued at about $220,000. 7.95% of the stock is currently owned by institutional investors.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.